dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Lakhani, Nehal |
dc.contributor.author | Cosman, Rasha |
dc.contributor.author | Banerji, Udai |
dc.contributor.author | Rasco, D. |
dc.contributor.author | Tomaszewska-Kiecana, Monika |
dc.contributor.author | GARRALDA, Elena |
dc.date.accessioned | 2024-02-26T12:41:15Z |
dc.date.available | 2024-02-26T12:41:15Z |
dc.date.issued | 2024-04 |
dc.identifier.citation | Lakhani N, Cosman R, Banerji U, Rasco D, Tomaszewska-Kiecana M, Garralda E, et al. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101). ESMO Open. 2024 Apr;9(4):102254. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/11119 |
dc.description | Inhibidor de punts de control; Retifanlimab; Tumor sòlid |
dc.description.sponsorship | This study was sponsored by Incyte Corporation (Wilmington, DE, USA) (no grant number). Medical writing was also funded by Incyte Corporation. The UK centers received National Institute of Health and Care Research Biomedical Research Centre funding (no grant number). |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;9(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Anticossos monoclonals - Ús terapèutic |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject.mesh | Antibodies, Monoclonal |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Treatment Outcome |
dc.subject.mesh | Antineoplastic Agents |
dc.title | A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2024.102254 |
dc.subject.decs | anticuerpos monoclonales |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | resultado del tratamiento |
dc.subject.decs | antineoplásicos |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2024.102254 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Lakhani N] START Midwest, Grand Rapids, USA. [Cosman R] Medical Oncology, The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, Darlinghurst, Australia. School of Medicine, University of New South Wales, Kensington, Australia. [Banerji U] Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. [Rasco D] START, San Antonio, USA. [Tomaszewska-Kiecana M] BioVirtus Research Site, Józefów, Poland. [Garralda E] Early Drug Development Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 38387109 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |